Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy

Ting-Kuang Yeh,Shio-Shin Jean,Yu-Lin Lee,Min-Chi Lu,Wen-Chien Ko,Hsueh-Ju Lin,Po-Yu Liu,Po-Ren Hsueh
DOI: https://doi.org/10.1016/j.ijantimicag.2021.106475
IF: 15.441
2022-01-01
International Journal of Antimicrobial Agents
Abstract:Multidrug-resistant (MDR) bacterial infections in humans are increasing worldwide. The global spread of antimicrobial resistance poses a considerable threat to human health. Phage therapy is a promising approach to combat MDR bacteria. An increasing number of reports have been published on phage therapy and the successful application of antibacterials derived using this method. Additionally, the CRISPR-Cas system has been used to develop antimicrobials with bactericidal effects in vivo. The CRISPR-Cas system can be delivered into target bacteria in various ways, with phage-based vectors being reported as an effective method. In this review, we briefly summarise the results of randomised control trials on bacteriophage therapy. Moreover, we integrated mechanisms of the CRISPR-Cas system antimicrobials in a schematic diagram and consolidated the research on phage-delivered CRISPR-Cas system antimicrobials.
pharmacology & pharmacy,infectious diseases,microbiology
What problem does this paper attempt to address?